Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155975 | 1.00 | PLAU (0.54) | PLAUIDO1ANPEPHTR2AKDM1A | |
| SCHEMBL4024386 | 1.00 | PLAU (0.54) | PLAUIDO1ANPEPHTR2AKDM1A | |
| Acetic Acid SCHEMBL2393012 | 0.83 | MTNR1A (0.44) | PLAUIDO1ANPEPKDM1A | |
| SCHEMBL7458168 | 0.82 | PLAU (0.45) | PLAUIDO1ANPEPHTR2AKDM1A | |
| SCHEMBL3996873 | 0.82 | ANPEP (0.68) | PLAUIDO1ANPEPHTR2A | |
| SCHEMBL7458173 | 0.82 | PLAU (0.45) | PLAUIDO1ANPEPHTR2AKDM1A | |
| SCHEMBL30070669 | 0.82 | ANPEP (0.68) | PLAUIDO1ANPEPHTR2A | |
| SCHEMBL9515317 | 0.82 | ANPEP (0.68) | PLAUIDO1ANPEPHTR2A | |
| SCHEMBL11355392 | 0.82 | ANPEP (0.68) | PLAUIDO1ANPEPHTR2A | |
| SCHEMBL9515304 | 0.82 | ANPEP (0.68) | PLAUIDO1ANPEPHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1184376-B1 | NOVEL HETEROCYCLIC CARBOXAMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-02-02 | — | — | EP | claimed |
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| CN-100473640-C | Method for preparing optical pure trans 2,3-diamine-1,2,3,4-tetrahydrogenated naphthalene | SHANGHAI YAOMING KANGDE NEW FH (CN) | 2009-04-01 | — | — | CN | disclosed |
| CN-1623976-A | Method for preparing optical pure trans 2,3-diamine-1,2,3,4-tetrahydrogenated naphthalene | YAOMING KANGDE NEW FHARMACEUTI (CN) | 2005-06-08 | — | — | CN | disclosed |
| EP-1184377-B1 | Hepatobiliary magnetic resonance contrast agents | BRACCO INT BV (NL) | 2005-02-02 | — | — | EP | disclosed |
| EP-1184377-A1 | Hepatobiliary magnetic resonance contrast agents | BRACCO International B.V. (NL) | 2002-03-06 | — | — | EP | disclosed |
| EP-0670832-A1 | HEPATOBILIARY MAGNETIC RESONANCE CONTRAST AGENTS | BRACCO International B.V. (NL) | 1995-09-13 | — | — | EP | disclosed |
| WO-1995009161-A1 | HEPATOBILIARY MAGNETIC RESONANCE CONTRAST AGENTS | BRACCO INTERNATIONAL B.V. (NL) | 1995-04-06 | — | — | WO | disclosed |
| US-5358704-A | Hepatobiliary tetraazamacrocyclic magnetic resonance contrast agents | BRISTOL-MYERS SQUIBB (US) | 1994-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | PLAU 1069/4885IDO1 2327/4885ANPEP 1983/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | PLAU 1069/4885IDO1 2327/4885ANPEP 1983/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | PLAU 1100/4885IDO1 2338/4885ANPEP 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.